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Identification and treatment of bacterial infection is central to our management of bronchiectasis, 
whether caused by cystic fibrosis or by other underlying disorders.(1)  The pathophysiology of these 
diseases is understood to be a vicious cycle of infection, inflammation and tissue damage which we 
attempt to break by eradicating or suppressing pathogenic bacteria using inhaled, oral and 
intravenous antibiotics.(1, 2)  
Our understanding of this pathophysiology is being changed, however, by developments in molecular 
microbiology and genomics.  Non-culture based methods of identifying bacteria, viruses and fungi in 
the lungs of CF and bronchiectasis patients is a rapidly expanding field of research.  By utilising high-
throughput sequencing platforms to target conserved regions of DNA, such as the bacterial 16S rRNA 
gene, identification of the bacteria present in sputum, bronchoalveolar lavage (BAL) or upper airway 
swabs is possible without the need for microbial culture.(3)  There is potential to identify potential 
pathogens more sensitively, to identify non-culturable bacteria, to understand “phenotypes” of 
disease based on microbiota profiles, and to better understand the impact of treatment on microbes 
and the host response. 
Cystic fibrosis is perhaps the most intensively studied condition with respect to the lung microbiome.  
Recent data shows that the upper airway microbiome starts to change in CF infants in the first year of 
life with overgrowth of Staphylococcus even in children without antibiotic treatment.(4, 5)  As disease 
progresses, the proteobacteria increase in relative abundance with the emergence of “traditional” CF 
pathogens such as Pseudomonas spp.  Longitudinal studies have identified that the lung microbiota is 
stable over time, at least in the short term, and does not varying significantly during exacerbations.(6)  
One of the largest studies in CF patients to date (n=269) confirmed patterns of microbiota diversity 
observed in other smaller-scale studies; dysbiosis (a reduction in microbiota diversity with dominance 
of one or a few genera) is associated with more severe disease, age and increasing antibiotic use.(7)  
A subset of genera, namely Veillonella, Burkholderia, Prevotella, Streptococcus, Rothia and 
Actinomyces, appear to form a core CF microbiota whilst genera like Pseudomonas and Staphylococcus 
become more dominant as disease progresses.  Very few studies have extensive longitudinal follow 
up of patients or have data on the impact of therapies such as inhaled antibiotics or CFTR modulators; 
this will need to be addressed before the utility of microbiota data in clinical settings is fully realised.   
The microbiota in bronchiectasis has been less well studied than in CF; small studies have shown that 
it is diverse and relatively stable over time, with a reduction in diversity identified at exacerbations 
and also associated with increasing disease severity.(8)  Like CF, there are common shared genera such 
as Veillonella, Streptococcus and Prevotella with dominance of pathogens such as Pseudomonas or 
Haemophilus associated with increasing disease severity.(9)  Intriguingly, a randomized control trial 
(RCT) of erythromycin suggested that long term macrolide therapy, a common treatment strategy, 
may be associated with an increase in relative abundance of Pseudomonas spp.(9)  This is important 
because of the well-known association between Pseudomonas aeruginosa infection and poor clinical 
outcomes.(10)  Dominance of Pseudomonas spp. by sequencing has also been associated with more 
exacerbations and increased levels of inflammation such as matrix metalloproteinases.(9, 11)  
While there are increasing numbers of bronchiectasis microbiota studies, a significant percentage 
have arisen from a single RCT in Australia that included only patients with a history of 2 or more 
exacerbations in the previous year among other exclusion criteria.(9)  It has been shown that 52-93% 
of bronchiectasis patients in real-life are ineligible for RCTs.(12)  Larger studies from diverse 
populations are now needed.  
Studies show that individuals microbiota profiles vary significantly from each other; what is normal for 
one patient during disease stability may not be for another.  The key to being able to use microbiota 
data clinically will be a better understanding of how an individual patients microbiota changes over 
time, and how this is associated with altered lung inflammatory profiles, clinical phenotypes and 
clinical outcomes.  In both CF and bronchiectasis it appears that this change towards dysbiosis 
alongside changes in clinical and inflammatory profiles is clinically important and useful to stratify 
patients.  What is now needed is to determine if microbiota profiles can add to existing stratification 
methods such as the Bronchiectasis Severity Index, by providing additional prediction of exacerbations 
or treatment response.(13, 14)   
A barrier to effective implantation of microbiota data into practice is a lack of agreed technical 
approaches.  Sampling techniques and DNA extraction methods vary greatly.  Different regions of the 
16S rRNA gene have been sequenced and numerous different sequence analysis pipelines exist.  All of 
these can cause slight variation in the proportions of genera identified.  Contamination of samples or 
laboratory reagents with can cause misleading results if not identified and dealt with, particularly in 
low biomass samples.  These technical and bioinformatic challenges need to be overcome and 
methods standardised if microbiota data is to become useful in clinical care.   
The bacterial microbiota alone will not explain all the phenotypic diversity seen in CF and 
bronchiectasis patients.  Viruses, fungi and mycobacteria also contribute to the lung microbiome in 
the healthy lung, in CF and bronchiectasis disease stability and exacerbation.  Indeed for 
bronchiectasis no ‘virome’ or ‘mycobiota’ studies have been published to date, yet it is acknowledged 
that mycosis is becoming an increasing problem.(15)  In both CF and bronchiectasis, therapeutic and 
prophylactic use of antibiotics are key parts of the physicians’ arsenal, yet whilst the treatments may 
improve disease symptoms, the effect they have on the fungi, bacteria and viruses inhabiting the 
airway is still not known.  A better understanding how antibiotic usage in bronchiectasis and CF may 
contribute towards the development of a dysbiotic microbiome could lead towards better antibiotic 
stewardship in early disease to slow the development of dysbiosis and drug resistance. 
Microbial sequencing technologies are a powerful tool to understand these diseases as never before.  
Application of novel tools is not, however, an end in itself.  The challenge for the pulmonary research 
community is to now apply this technology to answer clinically important questions and allow 
microbiome science to have a meaningful impact on patient care.  
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